Blog

Top Trends in ADC Drug Development

Unlocking Insights: Top 5 Reasons to Incorporate Orthotopic GBM PDX Models into Your Preclinical Evaluation

The Vital Role of Highly Characterized Glioblastoma PDX Models in Preclinical Cancer Research: Insights from TD2's Most Recent Studies

 

Climbing the Mountain: Current Challenges in Early Phase Oncology Clinical Trials

The Significance of Preclinical Evaluation in CAR T-cell Therapy for Solid and Hematologic Tumors

Advancing Preclinical Cancer Research Through Metabolomics: Key Strategies for Biomarker Identification and Drug-Target Analysis in Immuno-Oncology

Orthotopic vs. Subcutaneous: Unpacking the Strengths and Limitations of Tumor Model Implantation Sites

Unveiling the Potential: 5 Ways DIO Mice Enhance Immuno-Oncology Discoveries

Rule-Based Approach in Early-Phase Oncology

Genetically Engineered Humanized Mouse Models: A Critical Tool for Studying Immunotherapy Drugs

Diet-Induced Obesity Tumor Models for Cancer Studies

LAB in focus: Leuconostoc mesenteroids in Health and Industry

The A-Z Guide of DMPK Assays and How to Find the Right One

Early Phase Oncology Trial Designs: Model-Based Approach

Early Phase Oncology Trial Designs: The Model-Assisted Approach

Butyrate production by Bifidobacterium bifidum

L.helveticus: A lactobacilli for cancer treatment

Probiotics in focus: How does L. reuteri affect gut health?

CAR T-cell Therapy Program Development: Key Considerations

Efficient Data Management: One Way to Expedite the Clinical Development Process

 

 

 

 

 

 

 

The Critical Significance of DMPK Studies in Preclinical Research